How many institutions held IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share in Q2 2025?

148 institutional investors reported IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share for Q2 2025. Use the holders table for investor-level position and value details.

Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON)

Q: What does CUSIP 254604101 represent in this 13F holders report?

CUSIP 254604101 is the security identifier for IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

CUSIP: 254604101

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 37,778,373
Total 13F shares: 34,069,403
Share change: +920,997
Total reported value: $1,804,405,782
Put/Call ratio: 4.6%
Price per share: $52.96
Number of holders: 148
Value change: +$52,373,227
Number of buys: 94
Number of sells: 66

Quarterly Holders Quick Answers

What is CUSIP 254604101?
CUSIP 254604101 identifies IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 254604101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Braden M. Leonard	3/4/5	10%+ Owner	— class O/S missing	5,247,500	$354,993,375	—	26 Oct 2022	3/4/5
FMR LLC	13F	Company	8.5%	3,224,381	$160,058,273	—	31 Mar 2025	13F
Atlas Venture Life Science Advisors, LLC	13F	Company	6.3%	2,384,456	$118,364,396	—	31 Mar 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F 13D/G	Company	4.1% from 13D/G	2,343,499	$116,331,290	—	31 Mar 2025	13F 13D/G
Atlas Venture Fund X, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,600,512	$108,274,637	—	23 Jan 2024	3/4/5
BlackRock, Inc.	13F	Company	5.5%	2,094,560	$103,973,959	—	31 Mar 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	4.6%	1,754,834	$87,109,960	—	31 Mar 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	4.2%	1,577,106	$78,287,542	—	31 Mar 2025	13F
JANUS HENDERSON GROUP PLC	13F	Company	3.8%	1,423,259	$74,452,384	—	31 Mar 2025	13F
Novo Holdings A/S	3/4/5	10%+ Owner	— class O/S missing	1,090,772	$73,790,726	—	28 Jun 2023	3/4/5
ORBIMED ADVISORS LLC	13D/G 3/4/5 13F	Director · Company	4.5%	1,556,369	$73,382,798	$0	10 Mar 2025	13D/G 3/4/5 13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	3.6%	1,358,254	$67,425,000	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	3.5%	1,305,046	$64,782,484	—	31 Mar 2025	13F
Paradigm Biocapital Advisors LP	13F 13D/G	Company	3.5% from 13D/G	1,210,971	$60,112,600	—	31 Mar 2025	13F 13D/G
Frazier Life Sciences Public Fund, L.P.	13D/G	—	3%	1,026,489	$57,339,676	$0	30 Jun 2025	13D/G
Siren, L.L.C.	13F	Individual	2.8%	1,071,865	$53,207,379	—	31 Mar 2025	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	2.6%	983,500	$48,820,940	—	31 Mar 2025	13F
Bain Capital Life Sciences Opportunities III, LP	13D/G	—	3.3%	983,500	$46,372,025	$0	31 Dec 2024	13D/G
STATE STREET CORP	13F	Company	2.4%	918,567	$45,597,666	—	31 Mar 2025	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.1%	782,333	$38,835,010	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	2%	759,338	$37,693,539	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	571,984	$28,399,604	—	31 Mar 2025	13F
James B. Tananbaum	3/4/5	Director, 10%+ Owner	— mixed-class rows	428,745 mixed-class rows	$27,837,975	—	04 Oct 2021	3/4/5
Saturn V Capital Management LP	13F	Company	1.4%	518,177	$25,722,306	—	31 Mar 2025	13F
Woodline Partners LP	13F	Company	1.3%	502,230	$24,930,697	—	31 Mar 2025	13F
TCG Crossover Management, LLC	13F	Company	1.2%	465,257	$23,095,357	—	31 Mar 2025	13F
ARMISTICE CAPITAL, LLC	13F	Company	1.2%	436,000	$21,643,040	—	31 Mar 2025	13F
Logos Global Management LP	13F	Company	1%	394,342	$19,575,137	—	31 Mar 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.79%	300,000	$14,892,000	—	31 Mar 2025	13F
Foresite Capital Management V, LLC	13F	Company	0.79%	299,069	$14,845,785	—	31 Mar 2025	13F
Atlas Venture Opportunity Fund II, L.P.	3/4/5	10%+ Owner	— class O/S missing	218,326	$14,769,754	—	29 Dec 2022	3/4/5
Checkpoint Capital L.P.	13F	Company	0.64%	243,311	$12,077,958	—	31 Mar 2025	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.63%	236,471	$11,738,420	—	31 Mar 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	0.58%	219,603	$10,901,093	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.55%	208,813	$10,365,476	—	31 Mar 2025	13F
Dr. Mona Ashiya	3/4/5	Director	— mixed-class rows	196,541 mixed-class rows	$10,093,734	—	11 Jun 2025	3/4/5
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.52%	194,725	$9,666,149	—	31 Mar 2025	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.51%	193,664	$9,613,481	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.51%	191,220	$9,492,161	—	31 Mar 2025	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.48%	181,818	$9,025,446	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.45%	170,210	$8,449,273	—	31 Mar 2025	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.4%	150,000	$7,446,000	—	31 Mar 2025	13F
Nantahala Capital Management, LLC	13F	Company	0.39%	148,391	$7,366,129	—	31 Mar 2025	13F
Blue Owl Capital Holdings LP	13F	Company	0.37%	140,260	$6,962,506	—	31 Mar 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.37%	139,393	$6,923,070	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.35%	130,751	$6,490,479	—	31 Mar 2025	13F
Pictet Asset Management Holding SA	13F	Company	0.35%	130,386	$6,472,361	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.3%	112,717	$5,595,272	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.29%	108,499	$5,385,890	—	31 Mar 2025	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.26%	96,557	$4,793,090	—	31 Mar 2025	13F

Institutional Holders of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) as of Q2 2025

As of 30 Jun 2025, Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) was held by 148 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,069,403 shares. The largest 10 holders included FMR LLC, Atlas Venture Life Science Advisors, LLC, BlackRock, Inc., Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, ORBIMED ADVISORS LLC, and VANGUARD GROUP INC. This page lists 148 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

155

Q2 2025 holders

148

Holder diff

-7

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.